Sichuan Biokin Pharmaceutical (SHA:688506) subsidiary SystImmune has triggered the second $250 million near-term contingent payment under its global strategic cooperation agreement with Bristol Myers Squibb Yizekang project.
The milestone was achieved in the global third-phase pivotal registration clinical trial IZABRIGHT-Lung02 for Yizekang, according to a Tuesday filing with the Shanghai bourse.
Shares of the pharmaceutical company were down 4% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments